Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropinirole CR High-Dose in Parkinson's Disease
NCT01929317Phase 3Terminated
- Sponsor
- GSK
- Start
- Aug 2013
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ropinirole in Parkinson's disease (PD) (2 arms), sponsored by GSK. Primary endpoint: Unified Parkinson's Disease Rating Scale Part III (Motor Examination) Total Score at 12 weeks. Started Aug 2013; status: terminated.
02
Drugs
ropinirole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01929317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01929317.